Screener
Arcus Biosciences RCUS Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
FAQ
- What is Arcus Biosciences's contract liabilities?
- Arcus Biosciences (RCUS) reported contract liabilities of $56M in Q2 2026.
- How has Arcus Biosciences's contract liabilities changed year-over-year?
- Arcus Biosciences's contract liabilities decreased by 57.3% year-over-year, from $131M to $56M.
- What is the long-term trend for Arcus Biosciences's contract liabilities?
- Over 2 years (2023 to 2025), Arcus Biosciences's contract liabilities has grown at a -55.7% compound annual growth rate (CAGR), from $398M to $78M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about Arcus Biosciences's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude